David Telander
Retina Specialist · Sacramento, CANPI 1528043023
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (40.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alimera Sciences, Inc. at 24.8% of the total. Reporting peaked in 2023 at $4,730 and has fallen 59.8% since, to $1,901 in 2025.
Across 176 payments — averaging $100.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$4K
- Apellis Pharmaceuticals, Inc.$3K
- Regeneron$3K
- AbbVie$2K
- Genentech USA, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $3K from 14 others
Across 181 payments — averaging $4213.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$757K
- AbbVie$5K
- Notal Vision, Inc.$630
What the payments were for
- Consulting fees$7,08240%
- Speaking & faculty fees$3,70021%
- Food & beverage$6,84139%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 22 | $4,373 |
| Apellis Pharmaceuticals, Inc. | 19 | $3,050 |
| Regeneron | 6 | $2,957 |
| AbbVie(2 entities) | 5 | $2,149 |
| Genentech USA, Inc. | 28 | $1,148 |
| Regeneron Healthcare Solutions, Inc. | 33 | $1,052 |
| Astellas Pharma US Inc | 10 | $712 |
| Novartis | 16 | $462 |
| Mallinckrodt Hospital Products Inc. | 10 | $323 |
| Alcon | 2 | $252 |
| Biogen | 6 | $201 |
| Amgen | 3 | $190 |
| Genentech, Inc. | 3 | $180 |
| Bausch & Lomb Americas Inc. | 4 | $174 |
| Coherus Oncology, Inc. | 1 | $125 |
| Harrow Eye, LLC | 3 | $103 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Eyepoint US, Inc. | 1 | $37 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,623 in reported general payments places this provider in the 80th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 273 | $13,933 |
| Dorzolamide Hcl | 137 | $2,441 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $2,004 |
| Brinzolamide | 16 | $1,704 |
| Ketorolac Tromethamine | 49 | $1,669 |
| Ofloxacin | 110 | $1,064 |
| Brimonidine Tartrate | 35 | $1,058 |
| Acetazolamide | 23 | $509 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 25 | $424 |
| Timolol Maleate | 34 | $281 |
| Latanoprost | 18 | $234 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 33 | $186 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Sacramento
- Carlos Medina MendezSacramento$548K
- Margaret ChangSacramento$197K
- Glenn YiuSacramento$146K
- Joel PearlmanSacramento$33K
- Maryam GhiassiSacramento$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.